Fibromialgia: prevalencia, perfiles epidemiológicos y costes económicos

Cabo-Meseguer, Asensi; Cerdá-Olmedo, Germán; Trillo-Mata, José Luís

doi:10.1016/j.medcli.2017.06.008

Cited by 163 publications

(100 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fibromyalgia (FM) is a highly prevalent and disabling syndrome characterized by chronic widespread pain, fatigue, sleep difficulties and perceived cognitive dysfunction, without a curative treatment to date . FM is associated with remarkable levels of impairment and is characterized by elevated rates of unemployment and per‐patient costs .…”

Section: Introductionmentioning

confidence: 99%

Patients With Fibromyalgia Reporting Severe Pain but Low Impact of the Syndrome: Clinical and Pain‐Related Cognitive Features

et al. 2019

View full text Add to dashboard Cite

Background Fibromyalgia (FM) is a prevalent and highly disabling chronic pain syndrome. However, differences among patients regarding how pain impacts on daily life are remarkable. The main aim of this study was to identify clinical and pain‐related cognitive variables characterizing patients reporting high adaptability despite experiencing severe chronic pain. Methods Two hundred and eighty‐three Spanish patients with FM with high levels of pain were classified into 2 groups: (1) those reporting low impact of the syndrome, and (2) those with moderate‐to‐high impact. Perceived stress, anxiety, and depressive symptoms along with pain catastrophizing, psychological inflexibility, and perceived control over pain were evaluated. Differences in sociodemographics, years with FM, past/current major depressive disorder comorbidity, and health‐related economic costs (ie, medications, use of medical services, lost productivity due to sick leave) were also assessed. Stepwise logistic regression analyses predicting group membership from clinical variables and pain‐related cognitive processes as predictors were performed. Results Lower stress, anxiety, and depressive symptoms, along with reduced pain catastrophism, psychological inflexibility, and perceived control over pain, were found in the low‐impact group. Significant predictors of group membership (low‐impact vs. moderate‐to‐high impact) in regression analyses were “cognitive fusion” (psychological inflexibility), “helplessness” (pain catastrophizing), and depressive symptomatology, together with pain intensity and other FM symptoms. Conclusions The present study provides further evidence on resilience resources in chronic pain by identifying some variables (ie, reduced depressive symptomatology, pain catastrophizing, and psychological inflexibility) differentially characterizing a profile of patients with FM who are especially able to adapt to high levels of pain.

show abstract

Section: Introductionmentioning

confidence: 99%

Patients With Fibromyalgia Reporting Severe Pain but Low Impact of the Syndrome: Clinical and Pain‐Related Cognitive Features

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although possibly underestimated, the global prevalence for FM has been set at 2-8% and at 0.23-0.41 for ME/CFS with predominant ratios of females over males [13][14][15][16][17]. In addition, increasing numbers of patients being affected at early ages [18] highlights the considerable and raising needs for appropriate healthcare programs and the stepping demands for alleviation of associated economic/social burdens.…”

Section: Introductionmentioning

confidence: 99%

Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking back on Treatments

Almenar-Pérez

Sánchez-Fito

Ovejero

et al. 2019

Preprint

View full text Add to dashboard Cite

Fibromyalgia (FM) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are diseases of unknown etiology presenting complex and often overlapping symptomatology. Despite promising advances on the study of miRNomes of these diseases, no validated molecular diagnostic biomarker yet exists. Since FM and ME/CFS patient treatments commonly include polypharmacy it is of concern that biomarker miRNAs are masked by drug interactions. Aiming at discriminating between drug-effects and true disease-associated differential miRNA expression, we evaluated the potential impact of commonly prescribed drugs on disease miRNomes, as reported by the literature. By using the web search tools SM2miR, Pharmaco-miR and repoDB, we found a list of commonly prescribed drugs that impact on FM and ME/CFS miRNomes and therefore could be interfering in the process of biomarker discovery. On another end, disease-associated miRNomes may incline patient´s response to treatment and toxicity. Here, we explored treatments for diseases in general that could be affected by FM and ME/CFS miRNomes finding a long list of them, including treatments for lymphoma, a type of cancer affecting ME/CFS patients at a higher rate than healthy population. We conclude that FM and ME/CFS miRNomes could help refine pharmacogenomic/pharmacoepigenomic analysis to elevate future personalized medicine and precision medicine programs in the clinic.

show abstract

“…A principios de los años 90 la fibromialgia se definió como un síndrome cuyo síntoma principal es el dolor músculo-esquelético generalizado no explicable por la exploración clínica y en ausencia de enfermedad (Fiter, 1999;Goldenberg, 1994) y aún en la actualidad se mantiene esta concepción, subrayando su carácter crónico, de etiología desconocida y caracterizada por la presencia de dolor musculo-esquelético generalizado (Cabo-Meseguer, Cerdá-Olmedo y Trillo-Mata, 2017). Además del dolor, la fibromialgia se asocia a fatiga, alteraciones del sueño, rigidez matutina, ánimo deprimido, alteraciones cognitivas y un abanico de síntomas relacionados con el estrés y disfunciones neuroendocrinas e inmunológicas (Ángel-García, Martínez-Nicolás y Saturno-Hernández, 2016;Ballina, Martín, Iglesias, Hernández y Cueto, 1995;Cabo-Meseguer et al, 2017;Goldenberg, 1997;Wolfe et al, 1990).…”

Section: Definición Y Etimologíaunclassified

“…Un estudio posterior vuelve a estimar que la prevalencia de la fibromialgia en población española es del 2,37% para ambos sexos, siendo más frecuente en mujeres (4.2%) que hombres (0.2%) y suponiendo una relación de 21:1 (Mas, Carmona, Valverde y Ribas, 2008). Este dato de prevalencia en torno al 2,4% se considera vigente en la actualidad, apareciendo citado en numerosos trabajos y revisiones actuales 16 (Buitrago, Tejero, Gato, Rivera y Pérez, 2017;Cabo-Meseguer, Cerdá-Olmedo y Trillo-Mata, 2017).…”

Section: Prevalenciaunclassified

“…Por ejemplo, en el estudio de Branco et al (2010) se obtiene una prevalencia general para España similar a la del estudio EPISER, pero con una proporción de mujer/hombre de 2,5:1. Atendiendo a ambos datos y a la experiencia clínica subyacente a las diferentes guías clínicas parece más prudente ubicar la proporción mujer/hombre en un punto intermedio (Cabo-Meseguer et al, 2017), en esta línea la guía del Ministerio de Sanidad del 2011 establece una proporción de 9:1.…”

Section: Prevalenciaunclassified

See 1 more Smart Citation

Tratamiento de la fibromialgia en pacientes con afectación emocional durante programas cognitivo-conductuales y sin componente de expresión de las emociones a través del dibujo

Diego¹

View full text Add to dashboard Cite

Fibromialgia: prevalencia, perfiles epidemiológicos y costes económicos

Cited by 163 publications

References 23 publications

Patients With Fibromyalgia Reporting Severe Pain but Low Impact of the Syndrome: Clinical and Pain‐Related Cognitive Features

Patients With Fibromyalgia Reporting Severe Pain but Low Impact of the Syndrome: Clinical and Pain‐Related Cognitive Features

Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking back on Treatments

Tratamiento de la fibromialgia en pacientes con afectación emocional durante programas cognitivo-conductuales y sin componente de expresión de las emociones a través del dibujo

Contact Info

Product

Resources

About